Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial

Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial Publisher Pubmed

Malekzadeh R¹ ; Abedini A² ; Mohsenpour B³ ; Sharifipour E⁴ ; Ghasemian R⁵ ; Javadmousavi SA⁶ ; Khodashahi R⁷ ; Darban M⁸ ; Kalantari S⁹ ; Abdollahi N¹⁰ ; Salehi MR¹¹ ; Rezaei Hosseinabadi A¹² ; Khorvash F¹³ ; Valizadeh M¹⁴ Show All Authors

Malekzadeh R¹
Abedini A²
Mohsenpour B³
Sharifipour E⁴
Ghasemian R⁵
Javadmousavi SA⁶
Khodashahi R⁷
Darban M⁸
Kalantari S⁹
Abdollahi N¹⁰
Salehi MR¹¹
Rezaei Hosseinabadi A¹²
Khorvash F¹³
Valizadeh M¹⁴
Dastan F^{2, 15}
Yousefian S^{2, 15}
Hosseini H¹⁶
Anjidani N¹⁷
Tabarsi P¹⁴

Source: International Immunopharmacology Published:2020

Abstract

Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and immunomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patients with severe and critical COVID-19. Tocilizumab was added to the standard care of therapy at a dose of 324 mg (<100 kg bodyweight) or 486 mg (≥100 kg bodyweight). The study endpoints were all-cause mortality rate, changes in oxygen-support level, oxygen saturation, body temperature, respiratory rate, and laboratory variables during the study, and drug safety. Of 126 patients enrolled, 86 had severe and 40 had critical disease. Most patients were male (63.49%) and aged below 65 (78.57%). By day 14 of the study, 4.65% (4/86) of severe patients and 50.00% (20/40) of critical patients died. By the end, 6.98% (6/86) of severe patients and 60.00% (24/40) of critical patients died. Outcomes concerning three additional endpoints (oral temperature, oxygen saturation, and respiratory rate) were significantly improved as early as three days after tocilizumab administration in both groups of subjects, more considerably in severe patients. Significant improvement in the required level of oxygenation was reported in severe patients seven days after tocilizumab administration. No tocilizumab-related serious adverse event occurred in this study. Subcutaneous tocilizumab might improve some clinical parameters and reduce the risk of death in COVID-19 patients, particularly if used in the early stages of respiratory failure. © 2020

Related Docs

View other Related Docs

1. Efficacy and Safety of Tocilizumab in Severe and Critical Covid-19: A Systematic Review and Meta-Analysis, Expert Review of Clinical Immunology (2021)

2. Tocilizumab in Icu-Admitted Covid-19 Patients: A Retrospective Study, Medical Journal of the Islamic Republic of Iran (2023)

3. Efficacy of Tocilizumab in the Treatment of Covid-19: An Umbrella Review, Reviews in Medical Virology (2022)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (5)

Kourosh Sadeghi (1)

Style	Citing Format
MLA	Malekzadeh R, et al.. "Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial." International Immunopharmacology, vol. 89, no. , 2020, pp. -.
APA	Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javadmousavi SA, Khodashahi R, Darban M, Kalantari S, Abdollahi N, Salehi MR, Rezaei Hosseinabadi A, Khorvash F, Valizadeh M, Dastan F, Yousefian S, Hosseini H, Anjidani N, Tabarsi P (2020). Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial. International Immunopharmacology, 89(), -.
Chicago	Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javadmousavi SA, Khodashahi R, et al.. "Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial." International Immunopharmacology 89, no. (2020): -.
Harvard	Malekzadeh R et al. (2020) 'Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial', International Immunopharmacology, 89(), pp. -.
Vancouver	Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javadmousavi SA, et al.. Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial. International Immunopharmacology. 2020;89():-.
BibTex	@article{ author = {Malekzadeh R and Abedini A and Mohsenpour B and Sharifipour E and Ghasemian R and Javadmousavi SA and Khodashahi R and Darban M and Kalantari S and Abdollahi N and Salehi MR and Rezaei Hosseinabadi A and Khorvash F and Valizadeh M and Dastan F and Yousefian S and Hosseini H and Anjidani N and Tabarsi P}, title = {Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial}, journal = {International Immunopharmacology}, volume = {89}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Malekzadeh R AU - Abedini A AU - Mohsenpour B AU - Sharifipour E AU - Ghasemian R AU - Javadmousavi SA AU - Khodashahi R AU - Darban M AU - Kalantari S AU - Abdollahi N AU - Salehi MR AU - Rezaei Hosseinabadi A AU - Khorvash F AU - Valizadeh M AU - Dastan F AU - Yousefian S AU - Hosseini H AU - Anjidani N AU - Tabarsi P TI - Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial JO - International Immunopharmacology VL - 89 IS - SP - EP - PY - 2020 ER -

Style

Citing Format

MLA

Malekzadeh R, et al.. "Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial." International Immunopharmacology, vol. 89, no. , 2020, pp. -.

APA

Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javadmousavi SA, Khodashahi R, Darban M, Kalantari S, Abdollahi N, Salehi MR, Rezaei Hosseinabadi A, Khorvash F, Valizadeh M, Dastan F, Yousefian S, Hosseini H, Anjidani N, Tabarsi P (2020). Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial. International Immunopharmacology, 89(), -.

Chicago

Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javadmousavi SA, Khodashahi R, et al.. "Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial." International Immunopharmacology 89, no. (2020): -.

Harvard

Malekzadeh R et al. (2020) 'Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial', International Immunopharmacology, 89(), pp. -.

Vancouver

Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javadmousavi SA, et al.. Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial. International Immunopharmacology. 2020;89():-.

BibTex

@article{ author = {Malekzadeh R and Abedini A and Mohsenpour B and Sharifipour E and Ghasemian R and Javadmousavi SA and Khodashahi R and Darban M and Kalantari S and Abdollahi N and Salehi MR and Rezaei Hosseinabadi A and Khorvash F and Valizadeh M and Dastan F and Yousefian S and Hosseini H and Anjidani N and Tabarsi P}, title = {Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial}, journal = {International Immunopharmacology}, volume = {89}, number = {}, pages = {-}, year = {2020} }

RIS

TY - JOUR
AU - Malekzadeh R
AU - Abedini A
AU - Mohsenpour B
AU - Sharifipour E
AU - Ghasemian R
AU - Javadmousavi SA
AU - Khodashahi R
AU - Darban M
AU - Kalantari S
AU - Abdollahi N
AU - Salehi MR
AU - Rezaei Hosseinabadi A
AU - Khorvash F
AU - Valizadeh M
AU - Dastan F
AU - Yousefian S
AU - Hosseini H
AU - Anjidani N
AU - Tabarsi P
TI - Subcutaneous Tocilizumab in Adults With Severe and Critical Covid-19: A Prospective Open-Label Uncontrolled Multicenter Trial
JO - International Immunopharmacology
VL - 89
IS -
SP -
EP -
PY - 2020
ER -

Science Communicator Platform

Authors

Abstract